The president of France tried to turn the tables on the Biden administration after calling for the patent waiver of the vaccine, accusing the “Anglo-Saxon” countries of disrupting the supply of life-saving jobs.
Emmanuel Macron said the existing barriers to the export of vaccines and ingredients and the need for voluntary projects to share doses with poorer countries were a manifestation of the intellectual property debate in the United States.
At the EU summit in the Portuguese city of Porto, he specifically targeted the United States and commented that the country preserves home-made doses of the vaccine for domestic use.
“Today, Anglo-Saxons have blocked large quantities of these ingredients and vaccines,” Macron said. “What is the real issue now? It’s not actually about intellectual property. You can give intellectual property to laboratories that don’t know how to produce it. “
Speaking in Porto, European Commission President Ursula von der Leyen said he was willing to take part in talks on an IP waiver, but added that other vaccine-producing regions would have to follow the EU and allow large parts of their production to be exported.
Catherine Tae, a top trade adviser to President Joe Biden, said the remarks came two days after the United States backed a waiver of intellectual property protection for the Kovid-19 vaccine. Such a move would allow drugmakers to develop “copyright” vaccines without fear of being sued for intellectual property rights violations.
The Biden administration’s proposal wrongly trampled on the European Union, and a Freezing The response from top member countries, including Germany, is at the home of the pharmaceutical company Bioentech, which, together with Pfizer, is developing one of the leading Covid-19 vaccines.
Macron said he was willing to discuss intellectual property, but that this was not a critical issue he needed to address as he maintained EU records on vaccine production and exports.
The EU argues that other barriers, such as export bans and limited availability of raw materials, had a more decisive effect than patent protection, the EU argues.
“Where we are not given an example [production] Power is restricted due to patent or other IP rights protection, ”said a commission official.
Von der Lane said that while he was “open” to discussing a patent waiver, such a move would not lead to a single additional dose of the vaccine in the short and medium term. Those involved in the IP waiver debate, like the European Union, should agree to “export a large portion of the amount being produced in the region,” he said in a clear challenge to the United States.
UNU has so far exported a dose of about 200 meters of the vaccine, an equal number of distributors to its own citizens, Von der Lane said. In contrast, very few vaccine shots have been left in the United States.
EU officials say the EU has given Washington advance notice of the patent Move Shortly before it was released on Wednesday, however, there was no suggestion or attempt to adjust the terms. “If you ask me what happens next, the first thing is what America means by the declaration they made – we saw nothing but a general statement,” an official said.
Brussels is now trying to decide how to respond, and W European leaders will discuss the issue at a summit in Porto on Friday evening.
“Whether it is waived or waived, the problem goes beyond that,” a commission official said Friday, referring to the need to keep supply chains open for the supply of 260 components of the MRNA vaccine from 19 countries.
Another issue, according to the official, is that access to patents is not the same as gaining knowledge to create vaccines. About 70 to 100 patents were involved in the development of the mRNA vaccine, the official said, adding that even access to all of them “does not give you a brief overview of how the vaccine should be made, but how and what technology you need to know”.
Brussels further argued that existing international agreements on intellectual property provide some flexibility in the sharing of vaccine IPs, including the possibility of mandatory licensing.
The EU has in recent months resisted a pressure led by India and South Africa under the World Trade Organization to waive patents for vaccines. Brussels has expressed concern that they will face international pressure to change position in the WTO talks scheduled for early June, although trade officials say the meeting is now likely to be held.
A senior official in the Beadon administration says the WTO now has the opportunity to come together to come up with a life-saving solution. “We are working with the private sector and all potential partners – to continue expanding vaccine production and distribution around the world and to increase the raw materials needed to produce these vaccines.”